As 2024 draws to a close, we’re celebrating a wonderful year of content.
From insightful expert Q&As and peer-reviewed articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the endocrinology community with high-quality, easily accessible content.
Here are just a few of our standout moments from the past year.
Most read article:
In this review Dimitrios Patoulias and colleagues discuss the current evidence on the efficacy and safety of bexagliflozin, which provides an important alternative treatment option for patients with T2D.
Most watched video:
MiniMed 780G safe and effective for children 2-6 years with type 1 diabetes
Prof. Tadej Battelino discusses the results of the LENNY trial, which evaluated the safety and effectiveness of the MiniMed 780G system in very young children.
Most listened to podcast:
The diabetes tech revolution: How closed-loop systems are transforming care
In this episode Diana Isaacs joins us to discuss ‘Closed-loop’ systems and highlights their future potential in the management of type 1 diabetes.
Most viewed news story:
SOUL results indicate oral semaglutide reduces MACE risk by 14% in adults with T2D
This articles reports on the topline results from the SOUL trial, showing that oral semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes (T2D) who have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).
Stay informed in 2025 – sign up for our newsletter and get the latest content delivered directly to your inbox.
